BioSpace News Archive

Alcyone Therapeutics Inc. announced the acceptance of four abstracts at the 25th American Society of Gene and Cell Therapy Annual Meeting, an event being held May 16-19, 2022, at the Walter E. Washington Convention Center in Washington, D.C. and virtually.

Catamaran Bio, Inc., a biotechnology company developing off‑the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced that the company will present two posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held in Washington, DC, on May 16-18, 2022.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25th ASGCT Annual Meeting being held May 16-19, 2022, in-person in Washington, D.C. and in a virtual format.

ImmunoGen, Inc. announced that on April 29, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 729,530 shares of its common stock to sixteen new employees under the ImmunoGen, Inc.

TScan Therapeutics, Inc. announced the acceptance of three abstracts at the upcoming American Society of Gene and Cell Therapy Annual Meeting, being held from May 16-19, 2022, both in Washington D.C. and virtually.

Jaguar Gene Therapy, a biotechnology company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, including those that affect sizeable patient populations, today announced two abstracts related to its JAG101 Type 1 galactosemia program will be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

TCR2 Therapeutics Inc. announced that on April 29, 2022, the Compensation Committee of the Board of Directors of TCR2’s approved the grant of inducement stock options covering an aggregate of 57,200 shares of TCR2’s common stock to 4 new non-executive employees.

Vera Therapeutics, Inc. (Nasdaq: VERA), , today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients will be delivered in a late-breaking oral presentation at the American Transplant Congress (ATC) 2022 in Boston, Massachusetts.

The global artificial intelligence in healthcare market size is predicted to surpass around USD 208.5 billion by 2030 from valued at USD 10.5 billion in 2021, growing at a CAGR of 38.4% from 2022 to 2030.

The global Biotechnology Reagents & Kits market size is expected to hit around US$ 1.14 Trillion by 2030 from valued at US$ 437.28 billion in 2020 with a CAGR of 26.5% during forecast period 2021 to 2030.